Alzheimer's Disease: Update Bulletin #2 [April 2018]
This edition presents key opinion leader (KOL) views on recent developments in the Alzheimer’s Disease (AD) market. Topics covered include; results from the Phase IIa clinical study of EIP Pharma’s neflamapimod (VX-745); an overview of data for the Phase Ib/IIa COG010 study of Cognition Therapeutics’ Elayta (CT1812); the conclusion of the AMBAR (Alzheimer Management By Albumin Replacement) clinical trial investigating plasma exchange with Grifols’ human albumin solution, Albutein, combined with intravenous immunoglobulin (IVIG).
How successful do KOLs think that p38 MAP kinase alpha inhibition could prove to be as an approach for treating AD?
Do the results from the Phase IIa study with neflamapimod confirm its potential activity as a treatment for AD?
How important will the REVERSE-SD study be in terms of providing a better understanding of neflamapimod’s role as an AD therapy?
Do KOLs think that Elayta’s mechanism of action is compatible with it having a neuroprotective role in patients with AD?
Which types of patient are most likely to benefit from treatment with Elayta?
How do KOLs perceive plasma exchange as a method for reducing the beta-amyloid load in the brains of patients with AD?
Which factors are likely to influence the extent to which plasma exchange with Albutein/IVIG is utilised as a treatment for AD?
How do KOLs rate the chances of the AMBAR trial meeting its primary endpoint and plasma exchange therapy with Albutein/IVIG being successfully marketed?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook